Published in Eur Urol on January 17, 2008
Double anticholinergic therapy for refractory neurogenic and nonneurogenic detrusor overactivity in children: Long-term results of a prospective open-label study. Can Urol Assoc J (2014) 1.05
Effectiveness of combined high-dosed trospium and solifenacin depending on severity of OAB symptoms in elderly men and women under cyclic therapy. Cent European J Urol (2014) 1.02
Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol (2008) 0.82
Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance. Ther Adv Urol (2014) 0.81
Efficacy and tolerability of combined medication of two different antimuscarinics for treatment of adults with idiopathic overactive bladder in whom a single agent antimuscarinic therapy failed. Can Urol Assoc J (2013) 0.81
Triple therapy in refractory detrusor overactivity: a preliminary study. World J Urol (2009) 0.81
Refractory overactive bladder: a common problem? Int Urogynecol J (2015) 0.80
Medical management of neurogenic bladder with oral therapy. Transl Androl Urol (2016) 0.80
Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol (2016) 0.78
Maintenance of the therapeutic effect of two high-dosage antimuscarinics in the management of overactive bladder in elderly women. Int Neurourol J (2013) 0.78
Management of lower urinary tract dysfunction in patients with neurological disorders. Korean J Urol (2012) 0.77
Oxybutynin and trospium are substrates of the human organic cation transporters. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.77
Intravesical oxybutynin in the pediatric neurogenic bladder. Nat Rev Urol (2009) 0.76
Pediatrics: combining antimuscarinics shows promise for overactive bladder. Nat Rev Urol (2010) 0.75
An integrative review of standardized clinical evaluation tool utilization in anticholinergic drug trials for neurogenic lower urinary tract dysfunction. Spinal Cord (2016) 0.75
Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial. Ther Adv Urol (2016) 0.75
Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model. PLoS One (2017) 0.75
Survey of spinal cord injury-induced neurogenic bladder studies using the Web of Science. Neural Regen Res (2012) 0.75
The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection. Arab J Urol (2015) 0.75
Retracted Generation of pluripotent stem cells from adult human testis. Nature (2008) 5.49
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard? Eur Urol (2008) 3.27
In vitro investigations of tissue-engineered multilayered urothelium established from bladder washings. Eur Urol (2008) 2.84
Loss of nephrocystin-3 function can cause embryonic lethality, Meckel-Gruber-like syndrome, situs inversus, and renal-hepatic-pancreatic dysplasia. Am J Hum Genet (2008) 2.74
Urinary diversion. Urology (2007) 2.65
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
The periprostatic autonomic nerves--bundle or layer? Eur Urol (2008) 2.38
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol (2012) 2.29
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 2.19
Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy. BJU Int (2012) 1.99
Moderate degradation does not preclude microarray analysis of small amounts of RNA. Biotechniques (2003) 1.95
Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol (2010) 1.84
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
Minimally invasive percutaneous nephrolithotomy: an alternative to retrograde intrarenal surgery and shockwave lithotripsy. World J Urol (2012) 1.72
HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol (2009) 1.72
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol (2008) 1.68
Totally intracorporeal replacement of the ureter using whole-mount ileum. J Endourol (2014) 1.67
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63
Scribble participates in Hippo signaling and is required for normal zebrafish pronephros development. Proc Natl Acad Sci U S A (2009) 1.57
Y pouch neobladder-a simplified method of intracorporeal neobladder after robotic cystectomy. J Endourol (2014) 1.51
The commonly performed nerve sparing total prostatectomy does not acknowledge the actual nerve courses. J Urol (2009) 1.51
MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol (2006) 1.50
Urethral ultrasound as a screening tool for stricture recurrence after oral mucosa graft urethroplasty. Urology (2011) 1.50
Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria. Adv Urol (2011) 1.49
Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. Urology (2012) 1.47
The nephronophthisis gene product NPHP2/Inversin interacts with Aurora A and interferes with HDAC6-mediated cilia disassembly. Nephrol Dial Transplant (2013) 1.47
Quantification of tumor cell burden by analysis of single cell lymph node disaggregates in metastatic prostate cancer. Prostate (2010) 1.45
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43
Radical cystectomy and orthotopic bladder replacement in females. Eur Urol (2006) 1.42
The retinitis pigmentosa GTPase regulator interacting protein 1 (RPGRIP1) links RPGR to the nephronophthisis protein network. Kidney Int (2010) 1.42
Dorsal onlay skin graft urethroplasty in patients older than 65 years. Urology (2010) 1.41
Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue. Eur Urol (2007) 1.41
Prolonged percutaneous SNM testing does not cause infection-related explanation. BJU Int (2012) 1.41
Tissue engineering for the lower urinary tract: a review of a state of the art approach. Eur Urol (2007) 1.41
Steerable antegrade stenting: a new trick of the trade. Int Braz J Urol (2007) 1.39
Urinary calculi composed of uric acid, cystine, and mineral salts: differentiation with dual-energy CT at a radiation dose comparable to that of intravenous pyelography. Radiology (2010) 1.39
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol (2013) 1.38
Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol (2011) 1.36
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther (2010) 1.32
Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol (2009) 1.32
Expansion and differentiation of neural progenitors derived from the human adult enteric nervous system. Gastroenterology (2009) 1.32
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int (2014) 1.31
Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics (2006) 1.26
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol (2013) 1.25
Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol (2012) 1.25
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate (2009) 1.20
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res (2009) 1.19
Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol (2013) 1.18
A clinical trial alert tool to recruit large patient samples and assess selection bias in general practice research. BMC Med Res Methodol (2011) 1.15
Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer (2010) 1.14
Cell-surface heparan sulfate proteoglycans are essential components of the unconventional export machinery of FGF-2. Proc Natl Acad Sci U S A (2006) 1.13
Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety. Eur Urol (2008) 1.13
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol (2013) 1.12
Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med (2013) 1.11
Closing the tract of mini-percutaneous nephrolithotomy with gelatine matrix hemostatic sealant can replace nephrostomy tube placement. Urology (2006) 1.10
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm (2009) 1.10
HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol Immunother (2009) 1.08
Animal models of female stress urinary incontinence. J Urol (2008) 1.08
Urethrovaginal fistula--a rare complication after the placement of a suburethral sling (IVS). Int Urogynecol J Pelvic Floor Dysfunct (2006) 1.07
RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer (2007) 1.06
Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol (2010) 1.05
Accuracy of preoperative endorectal MRI in predicting extracapsular extension and influence on neurovascular bundle sparing in radical prostatectomy. World J Urol (2012) 1.04
Differentiation of urinary calculi with dual energy CT: effect of spectral shaping by high energy tin filtration. Invest Radiol (2010) 1.04
Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int (2012) 1.04
Regulation of ciliary polarity by the APC/C. Proc Natl Acad Sci U S A (2009) 1.03
Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother (2004) 1.03
In vitro myogenic differentiation of human bone marrow-derived mesenchymal stem cells as a potential treatment for urethral sphincter muscle repair. Ann N Y Acad Sci (2009) 1.02